Skip to Content

Christopher Garrett

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1988 University College Dublin, Belfield, Co. Dublin, Ireland, MD, Medicine

Postgraduate Training

7/1993-6/1997 Clinical Fellowship, Hematology/Oncology, Mayo Clinic, Rochester, MN
7/1991-6/1993 Clinical Residency, Internal Medicine, Mayo Clinic, Rochester, MN

Selected Publications

Peer-Reviewed Original Research Articles

1. Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol 68(2):547-52, 8/2011. e-Pub 4/24/2011. PMID: 21516509.
2. Garrett CR, Eng C. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 11(7):937-49, 7/2011. e-Pub 5/11/2011. PMID: 21557708.
3. Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DS. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer 105(1):44-52, 6/28/2011. e-Pub 5/31/2011. PMCID: PMC3137402.
4. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083-90, 3/10/2011. e-Pub 1/24/2011. PMCID: PMC3068054.
5. Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer. e-Pub 3/2011. PMCID: PMC3128184.
6. Mahmood ST, Vigil CE, Schell MJ, Zhao X, Han G, D'Amato GZ, Agresta S, Garrett CR, Chiappori AA. Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma. Int J Cancer, 12/2010.
7. Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. e-Pub 7/20/2010. PMID: 20644979.
8. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg 210(6):934-41, 6/2010. PMID: 20510802.
9. Fefilatyev S, chen L, Ivanovskiy TV, Hall LO, Goldgof DB, Greenstein H, Garrett CR. Complications in using automated methods to increase clinical trial accrual. Inter J Biomedical Eng & Tech 4(2):134-150, 2010.
10. Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res 15(18):5869-77, 9/2009. e-Pub 9/2009. PMID: 19737953.
11. Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer 100(12):1842-5, 6/2009. e-Pub 6/2009. PMCID: PMC2714236.
12. Haque W, Crane CH, Krishnan S, Delclos ME, Javle M, Garrett CR, Wolff RA, Das P. Reirradiation to the Abdomen for Gastrointestinal Malignancies. Radiat Oncol 18(4):55, 2009. PMCID: PMC2787526.
13. Hoda D, Simon GR, Garrett CR. Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. Ther Clin Risk Manag 4(6):1221-7, 12/2008. PMCID: PMC2643103.
14. Tolcher T, Mita A, Lewis L, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Anotnia S. A phase I and pharmacokinetic study of YM155, a small molecule inhibitor of survivin. J Clin Oncol 26(32), 2008, 11/2008.
15. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26(32). e-Pub 9/2008. PMID: 18824702.
16. Kaufman HL, Lenz HJ, Marshall J, Singh D, Garrett CR, Cripps C, Moore M, Von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB III, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL. Combination Chemotgherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 14(15):4843-4849, 8/2008.
17. Cangiano J, Centeno BA, Garrett CR, Cáceres W, de Jesús A, Lee JH, Pavía O, Jove R, Báez L, Sullivan DM, Muro-Cacho CA, Muñoz-Antonia T. Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies. Dig Dis Sci 53(8):2090-100, 1/2008. e-Pub 1/2008. PMID: 18224443.
18. Sagatys E, Garrett CR, Boulware D, Kelley S, Malafa M, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia. Hum Pathol 38(10):1526-31, 10/2007. PMID: 17640711.
19. Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 13(19):5855-61, 10/2007. PMID: 17908979.
20. Saglam O, Garrett CR, Boulware D, Sayegh Z, Shibata D, Malafa M, Yeatman T, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase AKT during the progression of colorectal neoplasia. Clin Colorectal Cancer 6(9):652-6, 9/2007. PMID: 17945038.
21. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22):3230-7, 8/2007. PMID: 17664471.
22. Holden JA, Willmore-Payne C, Coppola D, Garrett CR, Layfield LJ. High-resolution melting amplicon analysis as a method to detect c-kit and platelet-derived growth factor receptor alpha activating mutations in gastrointestinal stromal tumors. Am J Clin Pathol 128(2):230-8, 8/2007. PMID: 17638656.
23. Homsi J, Garrett CR. Melanoma of the anal canal: a case series. Dis Colon & Rectum. e-Pub 4/2007.
24. Fracasso PM, Burris H, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 13(3):986-93, 2/2007. PMID: 17289894.
25. Landau D, Garrett CR, Chodkiewicz C. A case of primary squamous cell colon cancer. J Oncol Pharm Pract 13(1):47-8, 2007.
26. Munster P, Marchion D, Bickaku E, Schmitt M, DeConti R, Simon GR, Fishman M, Garrett CR, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase I inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25(15):1979-85, 2007.
27. Galeb S, Kumar A, Djulbegovic BD, Lush R, Lancet J, Munster P, Daud A, Fishman F, Garrett C, Wenham R, Chiappori AA, Alsina M, Antonia S, Haura E, Dalton W, Sullivan D. Benefits and harms of phase I trials in oncology. JAMA. Submitted.
28. Demetri GD, Garrett CR, Schoffski P, Blackstein ME, Shah MH, Verweiji J, Leyvraz S, Hurwitz HI, Lopez-Ousa A, Le Cesne A, Goldstein D, Paz-Ares Rodrigues LG, Blay J, McArthur GA, Xu Q, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PG. Final results of a randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor after imatinib failure. J Clin Oncol. Submitted.

Abstracts

1. Hassabo HM, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). J Clinical Oncology 29(Suppl):3618 (#507), 2011.
2. Sharma S, Reid T, Hoosen S, Garrett CR, Beck J, Davidson S, MacKenzie M, Brandt U, Hecht J. Phase K stidu omvestogatomg RAD001 (everolimus), cetuximab, and irinotecan as a second-line therapy in metastatis colorectal cancer. Pro AM Soc Oncol (#15115). e-Pub 5/2009.
3. Garrett CR, Copola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacodynamic study of triciribine phosphate, a small molecule inhibitor of AKT phosphorylation, in adult subject with solid tumors containing phosphorylated AKT. AACR, 4/2009.
4. schoffski P, Huang X, Casali PG, Garrett CR, Blackstein ME, shah MH, Verweij J, Tassell V, Baum CM, Demetri GD. Phase III trial of sunitinib in imatinib-resistant/intolerant GIST with novel statistical analysis of long-term survival to account for crossover. ESMO 13:445, 9/2008.
5. Garrett CR, Siu LL, El-Khoueiry AB, Buter J, Rocha-Lima CM, Marshall JL, Kollia G, Velasquez L, Syed S. Feltquate D. A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab in patients with advanced hastrointestinal malignancies who failed prior therapy. Pro Am Cancer Soc:4111, 2008.
6. Yamauchi T, Garrett CR, Chodkiewicz C, Dinwoodie W, Jump H, Valone T, Lee J, Balducci L, Daud AI, Springett GM. A phase I trial of GemCap-T, capecitabine in combination with gemcitabine and erlotinib in patients with advanced pancreatic adenocarcinoma. Gastrointestinal Cancers Symposium(250), 2008.
7. Djulbegovic B, Moreno C, Kumar A, Lush R, Munster PH, Daud AI, Garrett CR, Simon GR, Lancet JE, Sullivan DM. Benefits (survival) and risks (30 days mortality) of phase I trials in oncology. Pro Am Soc Oncol:6508, 2008.
8. Blackstein M, Huang X, Demetri GD, Casali PG, Garrett CR, Schoffski P, Shah MH, Verweij J, Baum CM, DePrimo SE. Evaluation of soluble KIT as a potential surrogate marker for TTP in patients with advanced GIST receiving sunitinib. Gastrointestinal Cancers Symposium(19), 2008.
9. Iyer RV, Yu, Garrett CR, Litwin AM, Kuvshinoff B, Tarquini M, Webb N, Gibbbs J, Javle MM. Gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer: final results of the multicenter phase II study. Gastrointestinal Cancers Symposium(198), 2008.
10. Garrett CR, Huang X, Casali PG, Schoffski P, Blackstein ME< Shah M, Verweij J, Tassel V, Baum CM, Demetri GD. Long-term survival in a phase III trial of sunitnib in imatinib-resistant/intolerant gastrointestinal stromal tmor with novel statistical analysis to account for crossover. 10th World Congress on Gastrointestinal Cancer, Barcelona (#336), 2008.
11. Iyer RV, Yu J, Garrett CR, Litwin A, Khushalani N, Tarquini M, Webb N, Phelan J, Javle MM. Multicenter phase II study of gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer: final analysis of clinical and quality of life endpoints. Pro Am Soc Oncol:4616, 2008.
12. Demetri GD, Huang X, Garrett CR, et al. Novel statistical analysis of long-term survival to account for corssover in a phase III trial of sunitinib vs. placebo in advanced GIST after imatinib failure. Pro Am Soc Oncol:10524, 2008.
13. Hoda D, Catherine C, Strosberg J, Valone T, Jump H, Campos T, Greenstein H, WoodG, Hoffe S, Garrett CR. Phase II study of Sunitinib Malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma. Gastrointestinal Cancers Symposium (#267), 2008.
14. Vigil CE, Chiappori AA, Williams CA, Shrager HH, Murray BL, Letson DG, Sullivan DM, Garrett CR, D'Amato GZ, Agresta SV. Phase KK study of sunitinib malate in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas. Proceedings Am Soc Oncol:10535, 2008.
15. Garrett CR, Siu LL, Giaccone G, et al. A phase I study of BMS-582664 (brinivib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies. Proceedings of the American Society of Oncology:14018, 2007.
16. Sagatys E, Coppola D, Garrett CR. Activation of the serin/threonine kinase Akt in the progression of Barrett's neoplasia:8217, 2007.
17. Yamauchi T, Garrett CR, Chodkiewicz C, Dinwoodie W, Jump H, Valone T, Lee J, Balducci L, Daud AI, Springett GM. Clinical deployment of a medical expert system to increase accruals for clinical trials: challenges, systems, man and cybernetics, 2007. ISIC, IEEE International Conference, 2007.
18. Blackstein ME, Huang X, Demetri GD, Paolo, Casali G, Garrett CR, Schoffski P, Shah MH, Verweij J, Baum CM, DePrimo S. Evaluation of soluble KIT as a potential surrogate marker for time to progression in sunitinib-treated patients with advanced GIST. Proceedings of the American Society of Oncology:10007, 2007.
19. Holden JA, Wilmore-Payne C, Coppola D, Garrett CR, Layfield LJ. High frequency of platelet derived growth factor receptor alpha activating mutations in gastrointestinal stromal tumors: detection by high resolution melting amplicon analysis. United States and Candian Pathology Annual Meeting, 2007.
20. Blackstein ME, Huang X, Demetri GD, Casali PG, Garrett CR, Schoffski P, Shah MH, Berweij J, Gaum CM, DePrimo SE. Investigation of soluble KIT as a potential surrogate marker for time to progression in sunitinib-treated patients with gastrointestinal stromal tumors. 8th World Congress on Gastrointestinal Cancers, 2007.

Grant & Contract Support

Title: Southeast Phase II Cancer Consortium
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Dan Sullivan, MD
Duration: 1/1/2006 - 1/1/2011
 
Title: International Center of TCM for Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Lorenzo Cohen, PhD
Duration: 9/30/2005 - 8/31/2009

Last updated: 7/9/2013